Compounded tirzepatide vs. Zepbound: what the difference is

Zepbound is Eli Lilly's tirzepatide, approved for long-term weight reduction in adults with obesity, or overweight with a weight-related condition, and for moderate to severe obstructive sleep apnoea with obesity. It now comes in several formats, including the single-dose vials and four-dose KwikPen that LillyDirect sells for cash. The vial point matters: drawing a dose with a syringe is no longer a feature of compounding alone, because the brand vial asks the same of you.

What still separates them is the product itself. A Zepbound vial holds one fixed dose made to an approved specification. A compounded vial holds several doses at a concentration the pharmacy chose (Temi's listed vial is 17 mg/mL in 0.5 mL, so 8.5 mg in total, per usetemi.com, checked 28 Sep 2026), sometimes with an added ingredient such as glycine, and FDA does not review it before it is sold.

No trial compares compounded tirzepatide with Zepbound, so the honest comparison is between what each price buys.

A Zepbound vial buys the product behind SURMOUNT-1, where adults with obesity and without diabetes averaged −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg over 72 weeks, against −3.1% on placebo. The LillyDirect vial carries the same label as the pen, so that evidence applies to it directly.

A compounded vial buys tirzepatide by the milligram. Here is four weeks of drug at each dose, using LillyDirect's refill-on-time prices and Temi's lowest listed rate of $11.50 per mg (both checked 28 Sep 2026):

• 2.5 mg: Zepbound $299; compounded about $115
• 5 mg: Zepbound $399; compounded about $230
• 7.5 mg: Zepbound $449; compounded about $345
• 10 mg: Zepbound $449; compounded about $460
• 15 mg: Zepbound $449; compounded about $690

The compounded figures exclude Temi's $39 prescription service and any drug discarded at the 28-day mark. The Zepbound figures assume you refill within 45 days; miss it and LillyDirect charges $499 at 7.5 mg and $699 at 10 to 15 mg.

The label effects belong to tirzepatide, so expect the same list either way: nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions and fatigue are the reactions Zepbound's label reports in at least 5% of people, mostly around each dose step. The warnings cover pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration, and the rodent thyroid C-cell tumour boxed warning.

The compounded route adds measurement and handling risk. At 17 mg/mL, a 2.5 mg dose is about 15 units on a U-100 syringe and 15 mg is about 88 units, so a misread line moves more drug than people expect. FDA advises using a multi-dose vial within 28 days of first puncture, and it had counted more than 730 adverse event reports tied to compounded tirzepatide by 31 May 2026. A single-dose Zepbound vial is drawn in full once and discarded, which removes the 28-day question and most of the arithmetic.

Zepbound through LillyDirect makes most sense once you reach 10 mg or above and can refill on time, because $449 then buys as much drug as the compounded route or more, with the approved product and its trial evidence attached. It also makes sense if you have sleep apnoea, which is on Zepbound's label, or insurance that covers it.

Compounded tirzepatide makes most sense during the early steps, 2.5 to 7.5 mg, where the per-milligram gap is widest, and for people who cannot use LillyDirect. Go in knowing that FDA does not verify compounded products before sale.

A practical path some people discuss with their prescriber is starting on one and moving to the other as the dose rises. Tell your prescriber before you change products, and check the price at your own dose with our GLP-1 cost calculator rather than relying on a starting price.